Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers.

Trial Profile

Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2011

At a glance

  • Drugs Glucagon-like peptide-1 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jan 2011 Last checked against ClinicalTrials.gov record.
    • 18 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top